Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP: BICX )

0.3000 UNCHANGED
Streaming Delayed Price Updated: 11:55 AM EDT, Aug 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 0.3000
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3000
Today's Range 0.3000 - 0.3000
52wk Range 0.2820 - 1.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioCorRx Reports Business Update for the Second Quarter of 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death Intellectual Property
Exposures Death Intellectual Property

Performance

YTD
-58.62%
-58.62%
1 Month
-38.78%
-38.78%
3 Month
-61.54%
-61.54%
6 Month
-64.11%
-64.11%
1 Year
-82.14%
-82.14%

More News

Read More
BioCorRx Reports Business Update for the First Quarter of 2024
Via TheNewswire.com
Topics Death Intellectual Property
Exposures Death Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
BioCorRx Reports Business Update for 2023
Via NewMediaWire
Topics Death
Exposures Death
BioCorRx Reports Business Update for 2023
Via TheNewswire.com
Topics Death
Exposures Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Via TheNewswire.com
Topics Death
Exposures Death
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Via TheNewswire.com
Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
Via NewMediaWire
BioCorRx Reports Business Update for the Third Quarter of 2023
Via NewMediaWire
Topics Death
Exposures Death
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Via NewMediaWire
Exposures Product Safety
BioCorRx Reports Business Update for the Second Quarter of 2023
Via NewMediaWire
Exposures Product Safety
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Via NewMediaWire
Topics Death
Exposures Death Product Safety
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
BioCorRx Provides Business Update for the First Quarter of 2023
Via NewMediaWire
BioCorRx Provides Business Update for 2022
Via NewMediaWire
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Via NewMediaWire
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
Via NewMediaWire
Exposures Product Safety
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
Via NewMediaWire
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
Via NewMediaWire
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.